Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Abstract Background High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to immune checkpoint inhibitors and has been shown to be more significantly associated with response to PD-1 and PD-L1 blockade immunotherapy than PD-1 or PD-L1 expression, as measured by immunohistochemis...

Full description

Bibliographic Details
Main Authors: Zachary R. Chalmers, Caitlin F. Connelly, David Fabrizio, Laurie Gay, Siraj M. Ali, Riley Ennis, Alexa Schrock, Brittany Campbell, Adam Shlien, Juliann Chmielecki, Franklin Huang, Yuting He, James Sun, Uri Tabori, Mark Kennedy, Daniel S. Lieber, Steven Roels, Jared White, Geoffrey A. Otto, Jeffrey S. Ross, Levi Garraway, Vincent A. Miller, Phillip J. Stephens, Garrett M. Frampton
Format: Article
Language:English
Published: BMC 2017-04-01
Series:Genome Medicine
Subjects:
Tumor mutational burden
Cancer genomics
Mismatch repair
PMS2
Online Access:http://link.springer.com/article/10.1186/s13073-017-0424-2

Internet

http://link.springer.com/article/10.1186/s13073-017-0424-2

Similar Items